Measuring The Impacts Of Federal Investments In Research

The enactment of the America COMPETES Act in 2006 (and its reauthorization in 2010), the increase in research expenditures under the 2009 American Recovery and Reinvestment Act (ARRA), and President Obama's general emphasis on the contribution of science and technology to economic growth have all heightened interest in the role of scientific and engineering research in creating jobs, generating innovative technologies, spawning new industries, improving health, and producing other economic and societal benefits. Along with this interest has come a renewed emphasis on a question that has been asked for decades: Can the impacts and practical benefits of research to society be measured either quantitatively or qualitatively? On April 18-19, 2011, the Board on Science, Technology, and Economic Policy (STEP) and the Committee on Science, Engineering and Public Policy (COSEPUP) of the National Academy of Sciences, the National Academy of Engineering, and the Institute of Medicine, held a workshop to examine this question. The workshop sought to assemble the range of work that has been done in measuring research outcomes and to provide a forum to discuss its method. The workshop was motivated by a 2009 letter from Congressman Rush Holt (D-New Jersey). He asked the National Academies to look into a variety of complex and interconnected issues, such as the short-term and long-term economic and non-economic impact of federal research funding, factors that determine whether federally funded research discoveries result in economic benefits, and quantification of the impacts of research on national security, the environment, health, education, public welfare, and decision making. Measuring the Impacts of Federal Investments in Research provides the key observations and suggestions made by the speakers at the workshop and during the discussions that followed the formal presentations.

This report examines the portfolio of research and development (R&D) expenditure surveys at the National Science Foundation (NSF), identifying gaps and weaknesses and areas of missing coverage. The report takes an in-depth look at the definition of R&D, the needs and potential uses of NSF's R&D data by a variety of users, the goals of an integrated system of surveys and other data collection activities, and the quality of the data collected in the existing Science Resources Statistics surveys.

In 1998, health expenditures in the United States accounted for 12.9% of national income-the highest share of income devoted to health in the developed world. The United States also spends more on medical research than any other country-in 2000, the federal government dedicated $18.4 billion to it, compared with only $3.7 billion for the entire European Union. In this book, leading health economists ask whether we are getting our money's worth. From an economic perspective, they find, the answer is a resounding "yes": in fact, considering the extraordinary value of improvements to health, we may even be spending too little on medical research. The evidence these papers present and the conclusions they reach are both surprising and convincing: that growth in longevity since 1950 has been as valuable as growth in all other forms of consumption combined; that medical advances producing 10% reductions in mortality from cancer and heart disease alone would add roughly $10 trillion-a year's GDP-to the national wealth; or that the average new drug approved by the FDA yields benefits worth many times its cost of development. The papers in this book are packed with these and many other surprising revelations, their sophisticated analysis persuasively demonstrating the massive economic benefits we can gain from investments in medical research. For anyone concerned about the cost and the value of such research-from policy makers to health care professionals and economists-this will be a landmark book.

American leadership in the world is built on the foundation of its economic strength. Yet the United States faces enormous economic competition abroad and threats to its economy at home. In How America Stacks Up: Economic Competitiveness and U.S. Policy, Edward Alden, Bernard L. Schwartz senior fellow at the Council on Foreign Relations and director of the Renewing America initiative, and Rebecca Strauss, associate director of Renewing America, focus on those areas of economic policy that are the most important for reinforcing America’s competitive strengths. Covering education, transportation, trade and investment, corporate tax, worker retraining, regulation, debt and deficits, and innovation, How America Stacks Up shows how, in a highly competitive global economy, these seemingly domestic issues are all crucial to U.S. success in the global economy. The line between domestic economic policy and foreign economic policy is now almost invisible, and getting these policies right matters for more than just U.S. living standards. The United States’ ability to influence world events rests on a robust, competitive economy. But without further investment in education, infrastructure, and innovation, Alden and Strauss show, the United States runs the risk of endangering its greatest competitive advantage. Through insightful analysis and engaging graphics, How America Stacks Up outlines the challenges faced by the United States and prescribes solutions that will ensure a healthy, competitive U.S. economy for years to come.

Written in response to a request from the Senate Committee on the Budget, this paper reviews the available data on the economic value of federal investments in infrastructure, education and training, and R&D. It focuses on the empirical evidence produced since July 1991, when CBO last analyzed the issue in the study "How federal spending for infrastructure and other public investments affects the economy."

The Government Performance and Results Act (GPRA), passed by Congress in 1993, requires that federal agencies write five-year strategic plans with annual performance goals and produce an annual report that demonstrates whether the goals have been met. The first performance reports are due in March 2000. Measuring the performance of basic research is particularly challenging because major breakthroughs can be unpredictable and difficult to assess in the short term. This book recommends that federal agencies use an "expert review" method to examine the quality of research they support, the relevance of that research to their mission, and whether the research is at the international forefront of scientific and technological knowledge. It also addresses the issues of matching evaluation measurements to the character of the research performed, improving coordination among agencies when research is in the same field, and including a human resource development component in GPRA strategic and performance plans.